-------------------------------------------------------------------------
Adjusted operating
28 5 income 60 50
Depreciation and
28 16 amortization 65 45
-------------------------------------------------------------------------
$ 56 $ 21 167% 190% Adjusted EBITDA $ 125 $ 95 32%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Adjusted EBITDA
17% 8% margin 15% 13%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
n/m = not meaningful
Consolidated revenues for the third quarter of 2007 were up 24% on a reported basis to $321 million compared to $258 million last year. Strong 9% revenue growth at Sciex, combined with $55 million of revenue from MD in the third quarter, pushed MDS Analytical Technologies revenues up 92%. MDS Pharma Services revenues increased 4% compared to the same period in 2006, as our late-stage MDS Pharma Services businesses continued their strong growth. MDS Nordion revenues were down 4% on a reported basis compared to the same period in 2006, as the prior year figures included the realization of deferred revenue associated with our Zevalin(R) contract, which expired in February 2007 and therefore had no impact in the third quarter of fiscal 2007.
On an organic basis, revenues grew by 3%, and adjusted EBITDA grew by 190%, which reconcile to reported growth as follows:
Adjusted
'/>"/>
| SOURCE MDS Inc. Copyright©2007 PR Newswire. All rights reserved |